We previously demonstrated that ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor that is approved for treating chronic lymphocytic leukemia, has therapeutic effects on AD pathologies, including amyloid-β (Aβ) deposition, tauopathy, neuroinflammation, and cognitive function, in mouse models of AD [4]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.